Bezmaksas piegāde pasūtījumiem virs 29€

  • check 10+ miljoni grāmatu
  • check Jaunumi katru dienu
  • check Vairāk nekā 1 miljons klientu mums uzticas
  • check Labas cenas un atlaides
  • check Piegāde visā Eiropā

Anxiolytics - Mike Briley,David Nutt

angļu valoda
2000-09-01
149,45 € 213,50 €

-30% ar kodu BOOKS

Piegādātāja noliktavā

Piegāde 10-16 darba dienu laikā

30 dienu atgriešanas politika

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of ... Pilns apraksts

Jums varētu patikt arī

Aprašymas

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

Vairāk informācijas

Autors Mike Briley, David Nutt
Izdevējs Springer Science & Business Media
Izlaides gads 2000
Vāka tips Cietais vāks
EAN 9783764360320
Rakstiet savu atsauksmi
Jūs vērtējat: Anxiolytics
Jūsu novērtējums:

Goodreads atsauksmes

149,45 € 213,50 €